跳至主要内容
临床试验/CTRI/2022/09/046093
CTRI/2022/09/046093尚未招募3 期

A randomized, controlled, open label trial of tofacitinib versus mycophenolate mofetil in diffuse systemic sclerosis

Institute of Postgraduate Medical Education and Research0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • a. Patients of diffuse systemic sclerosis, fulfilling the ACR classification criteria for diagnosis, will be enrolled in the study.
  • b. Patients will be positive for anti Scl-70
  • c. Patients have ILD by HRCT criteria, or pulmonary function testing, or both.

排除标准

  • a. Patients who have received tofacitinib or mycophenolate and other immunosuppressant in the last 3 months
  • b. Patients with pregnancy or breast-feeding
  • c. Patients with active systemic infections.
  • d. Patients with hepatitis B and C, HIV infections, tuberculosis and overlap syndromes
  • e. Patients with severe pulmonary hypertension (NYHA class IV)
  • f. Patient who had the history of thrombosis in the past.

研究者

发起方
Institute of Postgraduate Medical Education and Research

相似试验